Evidence map›Paper›PMID 37520572›Full record

SynthesisFrontiers in immunology2023

Two case reports and a systematic review of the literature on adult cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody.

Meihui Xu, Chi Ma, Ming Dong, Chunjie Guo, Simin Yang, Yue Liu, Xu Wang

Open access · goldAbstract readSystematic ReviewCase Reports
In one paragraph

Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Movement Disorders in MOGAD: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026
    Pooled it
  2. Clinical features of recurrent MOG antibody-associated cortical encephalitis in adults.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Characteristics of myelin oligodendrocyte glycoprotein antibody-associated meningoencephalitis.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Meihui XuDepartment of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China.
Chi MaDepartment of Neurosurgery, the First Hospital of Jilin University, Changchun, China.
Ming DongDepartment of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China.
Chunjie GuoDepartment of Radiology, the First Hospital of Jilin University, Changchun, China.
Simin YangDepartment of Radiology, the First Hospital of Jilin University, Changchun, China.
Yue LiuDepartment of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China.
Xu WangDepartment of Neurology and Neuroscience Center, the First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has gained recognition in recent years as an immune-mediated inflammatory demyelinating disease of the central nervous system. The clinical features and prognosis of MOGAD adult cerebral cortical encephalitis (adult CCE) have not been fully elucidated. This study aims to further characterize the clinical symptoms, magnetic resonance imaging (MRI) findings, and prognosis of CCE with anti-MOG antibody. Methods: We present two adult cases of CCE with anti-MOG antibody and summarize the clinical symptoms, magnetic resonance imaging (MRI) findings, and prognosis of this phenotype as per a completed systematic review of the literature. Results: We found a total of 39 cases of MOGAD adult CCE (36% females; average age of onset of 29 years). Among them, 85% had seizure, 82% had headache, 64% had cortical symptoms, 64% had fever, 54% had changes of consciousness, and 38% had ocular symptoms. All cases demonstrated cerebral cortical T2 fluid-attenuated inversion recovery (FLAIR) lesions on MRI. Of the 25 patients (with seizure or not) who had EEG reports, 76% of patients showed abnormal EEG. Cerebrospinal fluid (CSF) white blood cell count of 90% of patients and CSF total protein of 67% of patients were elevated. In 16 patients with available CSF cytology data, 11 (69%) had abnormal cytology findings with monocytic predominance. In the 15 cases for which MOG antibody IgG was tested in both serum and CSF, 14 (93%) demonstrated a higher positive MOG IgG titer in serum than CSF. The majority of patients were treated with immunosuppressive therapy (97% corticosteroids, 15% mycophenolate mofetil, 13% IVIg, 5% azathioprine, and 5% other). The majority of patients had a favorable prognosis after treatment, as exemplified by improved clinical symptoms and imaging. Two patients relapsed. Conclusions: The clinical presentation and prognosis of adult CCE remain less understood in comparison to more common MOGAD phenotypes. It is important to consider MOGAD as an underlying etiology for adult CCE, as early detection and immunotherapy may improve outcomes.

Indexed as

AutoantibodiesEncephalitisFemaleHumansImmunoglobulin GMaleMyelin-Oligodendrocyte GlycoproteinOligodendrogliaSeizuresAutoantibodiesImmunoglobulin GMyelin-Oligodendrocyte Glycoproteinadultcerebral cortical encephalitisMRImyelin oligodendrocyte glycoprotein antibodymyelin oligodendrocyte glycoprotein antibody-associated disease

Identifiers

PMID37520572
PMCPMC10380939
OpenAlexW4384406683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.